Trends in Antiviral Drug Development (eBook, ePUB)

Redaktion: Sofia, Michael J.; Wang, Zhengqiang

• Format: ePub

Produktbeschreibung

Hard-to-find insights from industry professionals on success strategies for developing the next generation of antiviral blockbuster drugs

Presented by industry professionals with a track record of discovering new drugs and treatments, Trends in Antiviral Drug Development describes successful development efforts for antiviral compounds and therapies that have entered the market or are currently in clinical trials. Viruses are ordered by their target tissue, in line with contemporary drug development that focuses on tissue-targeted therapeutics. Other key trends in antiviral therapy, such as the effort to develop long-acting drugs, are described for each virus type, enabling readers to follow the current and future state in this core area of contemporary drug development.

Trends in Antiviral Drug Development includes discussion on:

• Novel drugs against herpes viruses as well as the breakthrough drugs that cured HCV
• siRNA therapeutics, a new antiviral modality, and the drug candidates that are progressing toward achieving an HBV cure
• Drugs targeting viral entry, such as in HIV entry through attachment, co-receptor binding, and fusion
• Novel therapeutics against tropical diseases such as dengue fever and monkey pox

Trends in Antiviral Drug Development is an essential read for medicinal chemists, pharmaceutical chemists, virologists, and all professionals seeking to understand new ideas and approaches to combat the ever-expanding universe of viral infections.

---

Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in D ausgeliefert werden.

Produktdetails

• Verlag: Wiley-VCH GmbH
• Seitenzahl: 959
• Erscheinungstermin: 23. April 2025
• Englisch
• ISBN-13: 9783527845095
• Artikelnr.: 73971516

Autorenporträt

Michael J. Sofia, Ph.D. is the Co-founder and former Chief Scientific Officer of Arbutus Biopharma, Inc. where he established the programs in HBV-cure and coronaviruse therapeutics. During his career he has introduced numerous drugs into clinical development for both infectious diseases and inflammatory diseases, including the discovery and early development of sofosbuvir, which became the backbone of many HCV curative therapies. After graduating from the University of Illinois and spending time as an NIH research fellow, he held research and research management positions at Gilead Sciences, Pharmasset, Bristol-Myers Squibb, Transcell Technologies and Eli Lilly. He has received numerous awards for his work on hepatitis C including the 2015 ACS Heroes of Chemistry Award, 2016 IUPAC-Richter Prize, the 2016 Lasker-Debakey Award in Clinical Medical Research, and the 2017 Gertrude Elion Award.

Zhengqiang (ZQ) Wang, Ph.D. is Professor and Director of Chemistry at the Center for

Drug Design, College of Pharmacy, University of Minnesota. He studied chemistry at Nankai University (China) and obtained his Ph.D. from Wayne State University (USA). He was a postdoc associate with Prof. Bob Vince, the inventor of HIV drug abacavir. As an independent researcher, he has led the medicinal chemistry of multiple sponsored antiviral drug discovery projects targeting important human viral pathogens, including HIV-1, HBV, HCMV and SARS-CoV-2.

Inhaltsangabe

Preface
Introduction: Successes and Challenges in Antiviral Drug Development

Part I: Human Herpes Viruses
Chapter 1: Letermovir
Chapter 2: Pritelivir

Part II: Immunodeficiency Virus
Chapter 3: Dolutegravir
Chapter 4: Islatravir (EFdA)

Part III: Hepatitis Viruses
Chapter 5: Imdusiran
Chapter 6: ARO-HBV/JNJ-3989
Chapter 7: Sofosbuvir
Chapter 8: Lidipasvir and Valpatasvir

Part IV: Respiratory Viruses
Chapter 9: Presatovir
Chapter 10: Remdesivir
Chapter 11: Ensitrelvir
Chapter 12: VV-116
Chapter 13: Molnupiravir

Part V: Tropical Disease Viruses
Chapter 14: Mosnodenvir

Part VI: Orthopoxvirus
Chapter 15: Brincidofovir